Literature DB >> 26964717

Canine placenta: A promising potential source of highly proliferative and immunomodulatory mesenchymal stromal cells?

Nathalie Saulnier1, Julia Loriau2, Marine Febre2, Clément Robert2, Rodolphe Rakic2, Tancrède Bonte3, Samuel Buff3, Stéphane Maddens2.   

Abstract

In veterinary medicine, therapeutic mesenchymal stromal cells (MSC) have been traditionally isolated from adult bone marrow or adipose tissue. Neonatal tissues, normally discarded at birth from all species have become an alternative source of cells for regenerative medicine in the human clinic. These cells have been described as being more primitive, proliferative and immunosuppressive than their adult counterparts. Our objective was to examine if this phenomena holds true in dogs. Little information exists regarding canine neonatal MSC characterisation. In this study, we were able to both isolate, phenotype and assess the differentiation and immunomodulatory properties of MSC from canine foetal adnexa allowing us to compare their characteristics to their more well-known bone marrow (BM) cousins. Neonatal tissues, including amnion (AM), placenta (PL), and umbilical cord matrix (UCM) were collected from 6 canine caesarean sections. Primary cells were expanded in vitro for 5 consecutive passages and their proliferation measured. BM-MSC were isolated from 5 control dogs euthanised from other studies and grown in vitro using an identical protocol. All MSC lines were systematically evaluated for their ability to differentiate into 3 mesodermal lineages (adipocyte, osteocyte and chondrocyte) and phenotyped by cytometry and qPCR. In addition, the enzymatic activity of the key immunomodulatory marker indoleamine 2,3-dioxygenase (IDO) was evaluated for each MSC line. MSC displaying a fibroblastic appearance were successfully grown from all neonatal tissues. PL-MSC exhibited significantly higher proliferation rates than AM- and UCM-MSC (p=0.05). Cytometric analysis showed that all MSC express CD90, CD29, and CD44, while no expression of CD45, CD34 and MHC2 was detected. Molecular profiling showed expression of CD105 and CD73 in all MSC. Low levels of SOX2 mRNA was observed in all MSC, while neither NANOG, nor OCT4 were detected. All MSC differentiate into 3 mesodermal lineages. Following inflammatory stimulation, the activity of the immunomodulatory enzyme IDO was significantly higher in neonatal MSC compared to BM-MSC (p=0.009). Our results show that canine foetal adnexa cells share very similar properties to their adult equivalents but upon stimulation show significantly higher IDO immunomodulatory activity. Further studies will be needed to confirm the potential therapeutic benefits of these cells.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Canine neonatal tissue; IDO; Immunomodulation; Mesenchymal stromal cells

Mesh:

Substances:

Year:  2016        PMID: 26964717     DOI: 10.1016/j.vetimm.2016.02.005

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

1.  Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Period after Tibial Plateau Leveling Osteotomy: A Pilot Study.

Authors:  Mathieu Taroni; Quentin Cabon; Marine Fèbre; Thibaut Cachon; Nathalie Saulnier; Claude Carozzo; Stéphane Maddens; Fabrice Labadie; Clément Robert; Eric Viguier
Journal:  Front Vet Sci       Date:  2017-06-08

2.  Characterization and Immunomodulation of Canine Amniotic Membrane Stem Cells.

Authors:  Alessandra de Oliveira Pinheiro; Valéria M Lara; Aline F Souza; Juliana B Casals; Fabiana F Bressan; Paulo Fantinato Neto; Vanessa C Oliveira; Daniele S Martins; Carlos E Ambrosio
Journal:  Stem Cells Cloning       Date:  2020-05-07

3.  3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice.

Authors:  Junhao Deng; Miao Li; Fanqi Meng; Zhongyang Liu; Song Wang; Yuan Zhang; Ming Li; Zhirui Li; Licheng Zhang; Peifu Tang
Journal:  Cell Death Dis       Date:  2021-11-22       Impact factor: 8.469

Review 4.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

5.  Placenta-derived multipotent mesenchymal stromal cells: a promising potential cell-based therapy for canine inflammatory brain disease.

Authors:  Rogério Martins Amorim; Kaitlin C Clark; Naomi J Walker; Priyadarsini Kumar; Kyle Herout; Dori L Borjesson; Aijun Wang
Journal:  Stem Cell Res Ther       Date:  2020-07-22       Impact factor: 6.832

Review 6.  Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials.

Authors:  Magdalena Kulus; Rafał Sibiak; Katarzyna Stefańska; Maciej Zdun; Maria Wieczorkiewicz; Hanna Piotrowska-Kempisty; Jędrzej M Jaśkowski; Dorota Bukowska; Kornel Ratajczak; Maciej Zabel; Paul Mozdziak; Bartosz Kempisty
Journal:  Cells       Date:  2021-11-23       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.